Affordable Access to glp-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions
Clinical studies have found these medications may: Improve insulin sensitivity Support healthier blood sugar regulation Improve certain cardiovascular risk factors Reduce inflammatory signaling Improve lipid profiles in some patients Researchers continue to investigate whether some of these benefits may occur independently of weight loss, although many questions remain about how these medications should be used outside their approved indications
Who Should Not Take Semaglutide
All adults had a recorded diagnosis of obesity defined as BMI of 30 kg/m 2 or higher or BMI of 27 kg/m 2 to 29.9 kg/m 2 with at least one weight-related comorbidity
Self-pay patients should verify their compounding source holds active 503A licensure, request quality assurance documentation, and establish a follow-up schedule (typically 46 weeks post-initiation, then quarterly)
Packer M et al., SUMMIT, NEJM 2024 (NEJMoa2410027, PMID 39555826) : tirzepatide and HFpEF with obesity, HR 0,62 composite endpoint
